- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 252
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Testosterone Greater Than 150 ng/dL
- Interventions
- Daratumumab, FMS Inhibitor JNJ-40346527, Radical Prostatectomy
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
- Drug
- Lead sponsor
- International Myeloma Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2031
- U.S. locations
- 10
- States / cities
- Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone, Carfilzomib, Daratumumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Plasma Cell Myeloma
- Interventions
- Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life Assessment, Interview
- Drug · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab SAR650984, Cemiplimab REGN2810
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Kansas City, Kansas • New York, New York + 1 more
- Conditions
- Amyloidosis
- Interventions
- Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg, Daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Duarte, California • San Francisco, California + 22 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Miami, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
- Conditions
- Multiple Myeloma (MM)
- Interventions
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Drug · Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
- Interventions
- Daratumumab, Dexamethasone, Ixazomib
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- daratumumab, carfilzomib, lenalidomide, dexamethasone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Low Dose Computed Tomography of the Whole Body, Magnetic Resonance Imaging, Positron Emission Tomography, Venetoclax, X-Ray Imaging, Questionnaire Administration
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer
- Interventions
- Daratumumab, KRAS vaccine, Nivolumab
- Drug · Biological
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- AL Amyloidosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
- Procedure · Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 117
- States / cities
- Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Daratumumab, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 5
- States / cities
- Yuma, Arizona • Denver, Colorado • Kansas City, Kansas + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, VELCADE (Bortezomib), Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stamford, Connecticut + 14 more
- Conditions
- Proliferative Glomerulonephritis With Monoclonal IgG Deposits
- Interventions
- Daratumumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Rochester, Minnesota • Chapel Hill, North Carolina + 1 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 397
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
- Conditions
- Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
- Interventions
- Tazemetostat, Tafasitamab, Lenalidomide, Acalabrutinib, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Santa Fe, California • Bolivar, Missouri • East Brunswick, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- Melphalan flufenamide (Melflufen), Dexamethasone
- Drug
- Lead sponsor
- Oncopeptides AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 9
- States / cities
- Whittier, California • Gainesville, Florida • Chicago, Illinois + 6 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab SAR650984, Bortezomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Kansas City, Missouri + 2 more
- Conditions
- Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
- Interventions
- CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax, Bortezomib, Ixazomib, Elranatamab, Teclistamab, Lenalidomide, Daratumumab
- Drug
- Lead sponsor
- CellCentric Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Bethesda, Maryland + 2 more
- Conditions
- High-risk Smoldering Multiple Myeloma, Multiple Myeloma
- Interventions
- Daratumumab, Bortezomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Omar Nadeem, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2030
- U.S. locations
- 6
- States / cities
- Stamford, Connecticut • Boston, Massachusetts • Foxborough, Massachusetts + 2 more
- Conditions
- Plasma Cell Myeloma, Secondary Amyloidosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis, Melphalan
- Procedure · Biological · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Nashville, Tennessee